Bristol Myers Squibb (BMY) Phase 3 Shows 59% PFS Risk Reduction vs Chemo

Tempus AI, Inc. (TEM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal real-world data, data

Bristol-Myers Squibb and SystImmune reported that their Phase 3 breast cancer trial met its primary endpoint. The interim results suggest the treatment's efficacy, which may impact future regulatory decisions and investor sentiment.

SystImmune and Bristol Myers Squibb (BMY) reported a 59% reduction in disease progression risk for iza-bren vs. chemotherapy in HR+/HER2- breast cancer. Trial showed 8.2m vs. 4.0m median PFS. BMY collaborates on iza-bren development outside China.

Bristol Myers Squibb's breast cancer drug, iza-bren, delayed disease progression for a median 8.2 months in a Phase 3 trial, versus 4 months with chemotherapy. The drug reduced the risk of progression or death, with manageable safety profile. Results will be presented at ESMO 2026. Iza-bren has shown clinical benefit in five tumor types, including breast and lung cancer, and has Breakthrough Therapy Designation. The drug is being developed under a license agreement with SystImmune.

Bristol-Myers Squibb (BMY) reported positive trial data for RYZ101 and progress in multiple myeloma, potentially broadening revenue sources. Q2 revenue grew 6% to $12.97B, with the Growth Portfolio up 15%. The company raised 2026 guidance to $49B-$50B in revenue and $6.75-$7.00 in non-GAAP EPS, but faces patent and generic pressure on older drugs.

HSBC reduced its price target for Bristol-Myers Squibb from $65 to $60. The stock is currently trading at $59.75, with a 5-day change of -1.35% and a year-to-date change of +10.77%.